Inflammatory disease drug developer Inflazome, based on research at University of Queensland and Trinity College Dublin, has added $45.6m in series B capital to its coffers.
Inflazome, an Ireland-based biotechnology spinout of University of Queensland that is developing drugs to block harmful inflammation, closed a €40m ($45.6m) series B round on Monday led by VC firm Forbion Capital Partners.
Novartis Venture Fund, an investment arm of pharmaceutical firm Novartis, also participated, as did Longitude Capital and Fountain Healthcare Partners.
Inflazome is developing therapies to tackle medical conditions caused by inflammation, such as neurological disorders like Alzheimer’s and Parkinson’s, as well as inflammatory bowel disease, gout, osteoarthritis, liver, kidney…
